DEA Rescheduling Hearing 2026: What Cannabis Industry Stakeholders Need to Know

Executive Summary

The Drug Enforcement Administration's 2026 rescheduling hearing represents the most consequential federal cannabis policy proceeding in half a century, with potential to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act. The administrative law judge hearing, expected to conclude in late 2026 or early 2027, follows the Department of Health and Human Services' August 2023 recommendation and the DEA's May 2024 Notice of Proposed Rulemaking. Market anticipation has driven the AdvisorShares Pure US Cannabis ETF (MSOS) to 2026 highs, with multi-state operators positioning for potential tax relief under Internal Revenue Code Section 280E and expanded institutional investment. The hearing will examine scientific evidence on cannabis's medical utility, abuse potential, and international treaty obligations, with testimony from federal agencies, medical researchers, industry representatives, and public health advocates. A Schedule III designation would not legalize cannabis federally but would fundamentally reshape the regulatory and economic landscape for the $30 billion domestic cannabis industry while maintaining federal prohibition for recreational use.

Why This Matters

The DEA rescheduling hearing will determine whether cannabis businesses gain access to standard tax deductions, potentially unlocking billions in capital and fundamentally altering the competitive dynamics of the legal cannabis market. Approximately 15,000 licensed cannabis businesses across 38 states currently operate under effective federal tax rates exceeding 70 percent due to 26 U.S.C. § 280E, which prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. Rescheduling to Schedule III would eliminate this barrier, immediately improving operator margins by 30-50 percent according to industry analysts. The proceeding affects multiple stakeholder groups with competing interests. Medical cannabis patients in 38 states and the District of Columbia rely on state-legal programs that exist in tension with federal prohibition. Multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Verano have invested over $10 billion in cultivation, processing, and retail infrastructure that operates under constant threat of federal enforcement. Institutional investors have largely avoided the sector due to Schedule I classification, with major banks refusing deposit accounts and payment processors declining merchant services. Public health researchers have faced decades of restrictions on cannabis studies due to Schedule I classification, which requires findings that a substance has "no currently accepted medical use" under 21 U.S.C. § 812(b)(1). The Food and Drug Administration has approved four cannabis-derived medications—Epidiolex, Marinol, Syndros, and Cesamet—creating a scientific contradiction with Schedule I criteria. State regulatory agencies in California, Colorado, Michigan, and other mature markets have developed sophisticated testing, tracking, and licensing frameworks that would gain federal recognition under Schedule III. The hearing's outcome will influence international drug policy, as the United States is a signatory to the 1961 Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances. Rescheduling would align U.S. policy more closely with recent reforms in Canada, Germany, Thailand, and other nations that have liberalized cannabis regulations while maintaining treaty compliance.

Background and History

Cannabis has been classified as a Schedule I controlled substance since the Controlled Substances Act took effect on May 1, 1971, placing it in the most restrictive category alongside heroin, LSD, and peyote. The classification occurred despite the National Commission on Marihuana and Drug Abuse—appointed by President Richard Nixon—recommending decriminalization in its March 1972 report "Marihuana: A Signal of Misunderstanding." The commission found that cannabis did not meet the criteria for Schedule I classification, but the Nixon administration rejected the findings.

Early Rescheduling Petitions (1972-2001)

The National Organization for the Reform of Marijuana Laws filed the first rescheduling petition in 1972, initiating a 22-year administrative process. DEA Administrative Law Judge Francis Young ruled in September 1988 that marijuana should be reclassified to Schedule II, finding that cannabis met the legal standard for "currently accepted medical use in treatment in the United States." Young wrote that marijuana was "one of the safest therapeutically active substances known to man" and that "it would be unreasonable, arbitrary and capricious for DEA to continue to stand between those sufferers and the benefits of this substance." DEA Administrator John Lawn rejected Judge Young's recommendation in December 1989, establishing a five-part test for "accepted medical use" that required FDA approval, large-scale clinical trials, published peer-reviewed studies, expert consensus, and recognition by qualified experts. The D.C. Circuit Court of Appeals upheld the DEA's authority to reject the ALJ recommendation in Alliance for Cannabis Therapeutics v. DEA, 15 F.3d 1131 (D.C. Cir. 1994). A second rescheduling petition filed by Jon Gettman in 1995 was denied in 2001, with the DEA citing lack of FDA-approved applications and insufficient clinical trials meeting modern standards. The agency maintained that Marinol (synthetic THC) approval in 1985 did not constitute evidence for whole-plant cannabis medical utility.

State-Level Legalization Era (1996-2020)

California voters approved Proposition 215 in November 1996, establishing the first state medical cannabis program and creating direct conflict with federal Schedule I classification. The Supreme Court ruled in United States v. Oakland Cannabis Buyers' Cooperative, 532 U.S. 483 (2001), that medical necessity was not a defense to federal prosecution, and in Gonzales v. Raich, 545 U.S. 1 (2005), that Congress had authority under the Commerce Clause to prohibit intrastate cannabis cultivation even for medical use. Colorado and Washington voters approved recreational cannabis legalization in November 2012, with sales beginning in January 2014. The Obama administration issued the Cole Memorandum in August 2013, establishing prosecutorial discretion guidelines that deprioritized enforcement in states with robust regulatory frameworks. Attorney General Jeff Sessions rescinded the Cole Memorandum in January 2018, but federal prosecutions of state-compliant businesses remained rare due to congressional appropriations riders prohibiting DOJ from using funds to interfere with state medical programs. By 2020, 33 states had established medical cannabis programs and 11 states had legalized recreational use, creating a $17.5 billion legal market operating entirely in violation of the Controlled Substances Act. The disconnect between state and federal law generated pressure for administrative rescheduling as a compromise short of full legalization.

Biden Administration Review (2022-2024)

President Joe Biden directed HHS Secretary Xavier Becerra and Attorney General Merrick Garland to review cannabis scheduling in October 2022, following through on a campaign commitment to decriminalize cannabis and expunge prior convictions. The directive specifically requested an expedited review under 21 U.S.C. § 811(a), which grants the Attorney General authority to reschedule substances based on HHS recommendations. HHS conducted a comprehensive scientific and medical evaluation coordinated by the FDA, examining eight factors specified in 21 U.S.C. § 812(b): actual or relative potential for abuse, scientific evidence of pharmacological effect, current scientific knowledge, history and current pattern of abuse, scope and significance of abuse, risk to public health, psychic or physiological dependence liability, and whether the substance is an immediate precursor of a controlled substance. The FDA's analysis reviewed over 30,000 published studies, consulted with the National Institute on Drug Abuse, and evaluated data from state regulatory agencies. HHS delivered its recommendation to reschedule cannabis to Schedule III on August 30, 2023, finding that cannabis has accepted medical use, lower abuse potential than Schedule I or II substances, and moderate to low physical dependence liability comparable to Schedule III substances like ketamine, anabolic steroids, and testosterone. The DEA received the HHS recommendation and initiated its own independent review under 21 C.F.R. § 1308.43-1308.45. The agency published a Notice of Proposed Rulemaking in the Federal Register on May 21, 2024, opening a 60-day public comment period that generated over 43,000 submissions—the most in DEA history for a rescheduling proceeding. Comments ranged from medical researchers supporting rescheduling based on therapeutic evidence to law enforcement organizations opposing any classification change and cannabis legalization advocates arguing for complete descheduling.

Hearing Announcement and Scheduling

The DEA announced in December 2025 that it would convene a formal administrative hearing under 21 C.F.R. § 1316.41-1316.67, appointing Administrative Law Judge Teresa Wallbaum to preside. The agency designated the hearing as a "legislative rule" proceeding under the Administrative Procedure Act, requiring the ALJ to compile a comprehensive record for final DEA review. The hearing is scheduled to begin in September 2026 at DEA headquarters in Arlington, Virginia, with an estimated duration of 8-12 weeks. The DEA identified 14 core issues for examination, including whether cannabis has currently accepted medical use in treatment in the United States, whether cannabis has a currently accepted medical use with severe restrictions, the actual or relative potential for abuse, and whether rescheduling would violate U.S. obligations under international drug control treaties. The agency granted participant status to 47 organizations including the FDA, HHS, National Institute on Drug Abuse, American Medical Association, American Academy of Pediatrics, National Cannabis Industry Association, Marijuana Policy Project, Smart Approaches to Marijuana, and individual state attorneys general from California, Colorado, Florida, and Texas.

Key Players

Drug Enforcement Administration

The DEA holds final authority over scheduling decisions under 21 U.S.C. § 811, though it must request a scientific and medical evaluation from HHS and give "significant weight" to the Secretary's recommendations. DEA Administrator Anne Milgram, appointed in June 2021, has emphasized evidence-based policy while maintaining the agency's law enforcement mission. The DEA's Diversion Control Division manages the scheduling process and coordinates with international regulatory bodies. The agency has historically taken conservative positions on cannabis rescheduling, rejecting multiple petitions over five decades, but faces unprecedented political and scientific pressure to align federal classification with state-level reforms and medical evidence.

Department of Health and Human Services

HHS conducts the scientific and medical evaluation required under 21 U.S.C. § 811(b), coordinating analysis across the FDA, National Institute on Drug Abuse, Centers for Disease Control and Prevention, and Substance Abuse and Mental Health Services Administration. Secretary Becerra's August 2023 recommendation represented the first time HHS has supported cannabis rescheduling in the Controlled Substances Act's 55-year history. The recommendation carries substantial weight in administrative proceedings, as courts have held that the DEA cannot reschedule a substance more restrictively than HHS recommends without clear evidence contradicting the medical evaluation.

Food and Drug Administration

The FDA evaluates whether cannabis meets the five-part test for "currently accepted medical use" established in prior DEA decisions. The agency has approved Epidiolex (cannabidiol) for seizure disorders, Marinol and Syndros (synthetic THC) for chemotherapy-induced nausea and AIDS wasting syndrome, and Cesamet (synthetic cannabinoid) for similar indications. FDA Commissioner Robert Califf has stated that whole-plant cannabis presents unique regulatory challenges due to variable cannabinoid profiles and lack of standardized dosing, but that evidence supports medical utility for specific conditions. The FDA's position on rescheduling directly influences the DEA's legal analysis of medical acceptance.

Multi-State Operators

Publicly traded MSOs including Curaleaf Holdings, Trulieve Cannabis, Green Thumb Industries, Verano Holdings, Cresco Labs, and Ayr Wellness collectively operate over 800 dispensaries and 100 cultivation facilities across state-legal markets. These companies have invested heavily in regulatory compliance infrastructure, laboratory testing, seed-to-sale tracking, and state lobbying. Rescheduling to Schedule III would eliminate 280E tax penalties, potentially improving EBITDA margins by 35-45 percent and enabling access to traditional banking services. Industry trade groups including the National Cannabis Industry Association, U.S. Cannabis Council, and Cannabis Trade Federation have coordinated advocacy efforts and submitted detailed economic impact analyses to the DEA.

Medical and Public Health Organizations

The American Medical Association has supported rescheduling to facilitate clinical research while maintaining that cannabis should be regulated through FDA approval processes. The American Academy of Pediatrics opposes rescheduling due to concerns about adolescent access and developmental impacts. The American Cancer Society Cancer Action Network supports rescheduling to enable research on cannabis for symptom management. These organizations' positions carry significant weight in administrative proceedings as evidence of medical community consensus or lack thereof.

Opposition Groups

Smart Approaches to Marijuana, led by former Representative Patrick Kennedy, opposes rescheduling and advocates for maintaining Schedule I classification or moving to Schedule II with strict prescription requirements. The organization argues that rescheduling would increase youth access, normalize use, and undermine prevention efforts. Law enforcement organizations including the National Sheriffs' Association and Major County Sheriffs of America have expressed concerns about impaired driving, diversion to illegal markets, and cartel involvement. These groups have requested participant status in the hearing to present evidence on public safety impacts.

Legal and Regulatory Framework

The Controlled Substances Act establishes a five-schedule classification system at 21 U.S.C. § 812, with placement determined by abuse potential, medical utility, and safety profile. Schedule I substances must have high abuse potential, no currently accepted medical use, and lack of accepted safety for use under medical supervision. Schedule III substances have lower abuse potential than Schedule I or II, currently accepted medical use, and moderate or low physical dependence or high psychological dependence potential. The rescheduling process follows procedures established in 21 U.S.C. § 811 and 21 C.F.R. Part 1308. The Attorney General (delegated to the DEA Administrator) may initiate rescheduling independently or in response to petitions from interested parties. The DEA must request a scientific and medical evaluation from HHS, which conducts an eight-factor analysis examining abuse potential, pharmacological effects, scientific knowledge, abuse patterns, public health risk, dependence liability, and whether the substance is an immediate precursor. HHS recommendations bind the DEA on scientific and medical matters under 21 U.S.C. § 811(b), which states that the Attorney General "shall" request an evaluation and "shall" consider the Secretary's recommendations as to scientific and medical matters. Courts have interpreted this language to mean the DEA cannot schedule a substance in a more restrictive category than HHS recommends without substantial evidence contradicting the medical evaluation. In Grinspoon v. DEA, 828 F.2d 881 (1st Cir. 1987), the First Circuit held that the DEA must give "serious consideration" to HHS recommendations but retains final authority. The Administrative Procedure Act governs the hearing process at 5 U.S.C. § 553-559, requiring notice, opportunity for public comment, and a reasoned explanation for the final decision. The DEA has designated this proceeding as formal rulemaking under 5 U.S.C. § 556-557, requiring an on-the-record hearing before an ALJ. The ALJ will compile a recommended decision based on the evidentiary record, which the DEA Administrator may adopt, modify, or reject. Final DEA decisions are subject to judicial review in federal circuit courts under 21 U.S.C. § 877. Internal Revenue Code Section 280E, enacted in 1982, prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. The provision was enacted in response to Jeffrey Edmondson's successful tax court case claiming deductions for a cocaine and marijuana trafficking operation. Cannabis businesses currently may deduct only cost of goods sold, resulting in effective tax rates of 70-90 percent. Rescheduling to Schedule III would eliminate 280E application, allowing standard business deductions for rent, salaries, marketing, and other operating expenses. The Rohrabacher-Farr Amendment, enacted annually since 2014 as Section 538 of the Commerce, Justice, Science Appropriations Act, prohibits the Department of Justice from using funds to prevent states from implementing medical cannabis laws. The provision does not protect recreational programs or create an affirmative right to violate the Controlled Substances Act, but has effectively prevented federal prosecution of state-compliant medical operators. Rescheduling would not affect this appropriations rider but would reduce the legal tension between state and federal law. International treaty obligations complicate rescheduling analysis. The 1961 Single Convention on Narcotic Drugs requires parties to limit cannabis to medical and scientific purposes and maintain strict controls. The United States submitted cannabis for Schedule I classification under the Convention, and rescheduling domestically may require notification to the United Nations Commission on Narcotic Drugs. The State Department has indicated that Schedule III classification would remain consistent with treaty obligations, as the Convention allows medical use with appropriate controls.

State-by-State Breakdown

California

California operates the largest state cannabis market with $5.3 billion in annual sales across 1,200 licensed retailers. The state legalized medical use in 1996 and recreational use in 2016, establishing the Bureau of Cannabis Control (now Department of Cannabis Control) to oversee licensing, testing, and enforcement. California allows possession of up to one ounce for adults 21+ and cultivation of six plants. The state has submitted comments supporting rescheduling to facilitate interstate commerce and banking access. Governor Gavin Newsom has advocated for federal reform to address the competitive disadvantage California operators face due to 280E taxation.

Colorado

Colorado launched recreational sales in January 2014, generating over $15 billion in total revenue and $2.5 billion in state tax collections through 2025. The state's Marijuana Enforcement Division licenses approximately 1,400 businesses under a seed-to-sale tracking system using METRC software. Colorado allows possession of up to one ounce and cultivation of six plants (12 per household). The state has developed sophisticated impaired driving protocols and youth prevention programs that federal agencies have studied as potential national models. Colorado Attorney General Phil Weiser has participated in the DEA proceeding, arguing that rescheduling would validate state regulatory frameworks while maintaining appropriate federal oversight.

Florida

Florida operates a medical-only program with over 800,000 registered patients and 25 licensed operators, generating $2.1 billion in annual sales. The state limits licenses to vertically integrated operators and prohibits smokable flower sales except for qualified patients. Florida does not allow home cultivation. A recreational legalization initiative is expected on the November 2026 ballot. Governor Ron DeSantis has opposed rescheduling, arguing that it would increase youth access and undermine prevention efforts, while state Attorney General Ashley Moody has submitted comments to the DEA expressing concerns about public safety impacts.

Illinois

Illinois legalized recreational use in January 2020 through the Cannabis Regulation and Tax Act, establishing a social equity licensing program to address communities disproportionately affected by prohibition. The state allows possession of 30 grams for residents and 15 grams for non-residents, with no home cultivation for recreational users. Illinois has generated over $1.8 billion in tax revenue, with 25 percent allocated to the Restore, Reinvest, and Renew Program for community reinvestment. The state has supported rescheduling in comments to the DEA, emphasizing the need for banking access and tax equity.

Michigan

Michigan voters approved recreational legalization in November 2018, with sales beginning in December 2019. The state allows possession of 2.5 ounces and cultivation of 12 plants for personal use. Michigan has issued over 1,800 licenses and generated $3.2 billion in total sales through 2025. The Cannabis Regulatory Agency oversees testing, packaging, and tracking requirements. Michigan has experienced rapid market growth and price compression, with wholesale flower prices declining from $3,000 per pound in 2020 to under $1,000 in 2026. State regulators have supported rescheduling to address interstate commerce restrictions and banking challenges.

New York

New York legalized recreational use through the Marijuana Regulation and Taxation Act in March 2021, with licensed sales beginning in December 2022. The state's Office of Cannabis Management has issued approximately 300 licenses, prioritizing social equity applicants. New York allows possession of three ounces and cultivation of six plants (12 per household). The state projects $1.25 billion in annual tax revenue at market maturity. New York has faced challenges with unlicensed storefronts and slow licensing rollout. Governor Kathy Hochul has supported rescheduling to facilitate banking and reduce illegal market competition.

Ohio

Ohio voters approved recreational legalization in November 2023 through Issue 2, with sales beginning in August 2024. The state allows possession of 2.5 ounces and cultivation of six plants (12 per household). Ohio's Division of Cannabis Control oversees approximately 400 licensed businesses. The state has generated over $400 million in tax revenue in the first year of recreational sales. Ohio has not taken an official position on federal rescheduling, though the state's medical program has operated successfully since 2019 with over 300,000 registered patients.

Texas

Texas maintains one of the most restrictive medical cannabis programs, limited to low-THC products (0.5 percent THC or less) for specific qualifying conditions. The state's Compassionate Use Program serves approximately 50,000 patients through 17 licensed dispensaries. Texas does not allow smokable products or home cultivation. Attorney General Ken Paxton has opposed rescheduling, arguing that it would conflict with state law and undermine public safety. Texas law enforcement organizations have submitted comments to the DEA expressing concerns about increased trafficking and impaired driving.

Market and Business Implications

Rescheduling to Schedule III would immediately improve cannabis operator profitability by 30-50 percent through elimination of 280E tax penalties, potentially unlocking $3-5 billion in annual tax savings across the industry. Multi-state operators currently pay effective federal tax rates of 70-90 percent because they cannot deduct rent, salaries, marketing, or other ordinary business expenses. Schedule III classification would allow standard deductions while maintaining federal prohibition on recreational use. The AdvisorShares Pure US Cannabis ETF (MSOS) reached $18.42 per share on June 8, 2026—a 47 percent increase year-to-date—driven by investor anticipation of the DEA hearing outcome. The fund holds positions in Curaleaf, Trulieve, Green Thumb Industries, Verano, and Cresco Labs, which have collectively gained an average of 52 percent in 2026. Options activity has increased substantially, with call volume on major MSOs up 180 percent compared to 2025 levels. Institutional investment remains limited due to federal prohibition and Schedule I classification. Major banks including JPMorgan Chase, Bank of America, and Wells Fargo do not provide deposit accounts or merchant services to cannabis businesses, forcing operators to rely on credit unions and regional banks willing to accept compliance risks. Rescheduling would not eliminate Controlled Substances Act violations but would signal federal tolerance and potentially encourage more financial institutions to enter the market. Wholesale cannabis prices have declined substantially in mature markets due to oversupply and competition. California wholesale flower prices averaged $800-1,000 per pound in early 2026, down from $1,500 in 2024 and $3,000 in 2020. Michigan, Oklahoma, and Oregon have experienced similar price compression. Operators have responded by consolidating cultivation facilities, investing in automation, and focusing on branded products with higher margins. Rescheduling-driven tax relief could stabilize struggling operators and prevent further market consolidation. Interstate commerce remains prohibited under the Controlled Substances Act regardless of scheduling classification. Cannabis cannot cross state lines even between legal markets, forcing operators to build redundant infrastructure in each state. Some legal scholars argue that Schedule III classification combined with state legalization could enable interstate commerce under the dormant Commerce Clause, but the DEA has indicated that rescheduling would not authorize interstate transfers without additional regulatory changes. Capital markets access would improve significantly under Schedule III. Cannabis companies cannot list on the New York Stock Exchange or Nasdaq due to federal prohibition, forcing them to trade on Canadian exchanges or over-the-counter markets with limited liquidity. Rescheduling could enable uplisting to major U.S. exchanges, improving access to institutional capital and reducing cost of equity. Debt financing would also become more available as banks gain comfort with federal policy direction. The hemp and CBD industry, legalized under the 2018 Farm Bill for products containing less than 0.3 percent delta-9 THC, would face new competition from Schedule III cannabis. Currently, hemp-derived products can be sold without state cannabis licenses, creating a parallel market. Rescheduling could prompt FDA regulation of all cannabinoid products, potentially restricting hemp-derived CBD sales and consolidating the market under state-licensed operators.

What Experts Say

Medical researchers have largely supported rescheduling to facilitate clinical trials and expand the evidence base for therapeutic applications. Dr. Nora Volkow, director of the National Institute on Drug Abuse, has stated that Schedule I classification creates unnecessary barriers to research while acknowledging that cannabis carries risks including dependence potential and cognitive impacts. According to Volkow, rescheduling would enable more rigorous study of dosing, delivery methods, and long-term effects while maintaining appropriate controls. The American Medical Association has advocated for rescheduling combined with FDA oversight of cannabis products. The organization's position emphasizes that medical use should be determined through clinical trials and regulatory approval rather than state ballot initiatives. The AMA has noted that whole-plant cannabis contains over 100 cannabinoids with varying pharmacological profiles, requiring standardization and quality control similar to other botanical medicines. Industry analysts project that rescheduling would increase cannabis company valuations by 40-60 percent through improved profitability and reduced regulatory risk. According to Pablo Zuanic of Zuanic & Associates, elimination of 280E would improve operator EBITDA margins from current levels of 10-20 percent to 35-45 percent, comparable to alcohol and tobacco companies. Zuanic has noted that institutional investors have avoided the sector due to federal prohibition, and rescheduling could trigger significant capital inflows. Law enforcement organizations have expressed concerns about rescheduling impacts on impaired driving enforcement and youth access. According to the National Sheriffs' Association, states with legal cannabis have experienced increases in traffic fatalities involving THC, though causation remains difficult to establish due to detection challenges. The organization has argued that Schedule III classification would normalize cannabis use and undermine prevention messaging, particularly for adolescents. Public health researchers have emphasized the need for continued monitoring of cannabis impacts on mental health, particularly for individuals with genetic predisposition to psychosis. Dr. Bertha Madras of Harvard Medical School has argued that rescheduling should not occur without comprehensive evaluation of potency increases in commercial products, which now commonly exceed 20-30 percent THC compared to 3-5 percent in the 1990s. According to Madras, high-potency products pose greater risks for cannabis use disorder and psychiatric complications. State regulators have supported rescheduling as validation of their licensing and enforcement frameworks. According to Shannon Fender, executive director of the Colorado Marijuana Enforcement Division, state programs have successfully implemented seed-to-sale tracking, product testing, and youth access prevention while generating substantial tax revenue. Fender has noted that federal rescheduling would facilitate interstate cooperation on best practices and enforcement coordination. Cannabis legalization advocates have argued that rescheduling is insufficient and that complete descheduling is necessary to address criminal justice impacts and enable full legalization. According to NORML deputy director Paul Armentano, Schedule III classification would maintain federal prohibition for recreational use and continue to criminalize possession in states without legal programs. Armentano has emphasized that rescheduling would benefit corporate operators while doing little for individuals with prior convictions or those in prohibition states.

What's Next

The DEA administrative hearing is scheduled to begin in September 2026 and continue for 8-12 weeks, with Administrative Law Judge Teresa Wallbaum presiding over testimony from federal agencies, medical experts, industry representatives, and public health advocates. The hearing will examine the eight factors specified in 21 U.S.C. § 812(b), with particular focus on whether cannabis has "currently accepted medical use" and whether abuse potential warrants Schedule III classification. Key testimony is expected from FDA officials regarding the agency's evaluation of Epidiolex and other approved cannabis-derived medications, NIDA researchers on abuse liability and dependence potential, and state regulatory officials on the effectiveness of licensing and enforcement frameworks. Industry representatives will present economic impact analyses and operational data on tax burdens under 280E. Opposition groups will present evidence on youth access, impaired driving, and public health concerns. The ALJ will compile a recommended decision based on the evidentiary record, expected in early 2027. The recommendation will include findings of fact, conclusions of law, and a proposed scheduling determination. DEA Administrator Milgram will review the recommendation and issue a final rule, which may adopt, modify, or reject the ALJ's conclusions. The DEA has indicated that it will issue a final decision within six months of receiving the ALJ recommendation, placing the likely timeline in mid-to-late 2027. If the DEA adopts Schedule III classification, the rule would take effect 30 days after publication in the Federal Register unless Congress exercises authority under the Congressional Review Act to disapprove the rule. Schedule III designation would immediately eliminate 280E application, allowing cannabis businesses to deduct ordinary expenses beginning in the tax year the rule takes effect. The FDA would gain authority to regulate cannabis products under the Food, Drug, and Cosmetic Act, potentially requiring approval applications for specific formulations and indications. Banking access would improve gradually as financial institutions assess regulatory risk and develop compliance frameworks. The Federal Reserve and Office of the Comptroller of the Currency would likely issue guidance on cannabis banking under Schedule III, though the Bank Secrecy Act would continue to require suspicious activity reporting for transactions involving Controlled Substances Act violations. The SAFE Banking Act, which would provide explicit protections for financial institutions serving cannabis businesses, remains pending in Congress and could advance more easily following rescheduling. State-level policy would continue to evolve independently of federal classification. Several states including Kentucky, North Carolina, and South Carolina are considering medical cannabis legislation in 2026-2027. Recreational legalization initiatives are expected on ballots in Florida, North Dakota, and South Dakota in November 2026. Federal rescheduling could accelerate state-level reforms by reducing political opposition and validating medical utility claims. International implications include potential pressure on other nations to reconsider cannabis classification under international drug control treaties. Canada, Germany, Thailand, and Malta have already implemented legalization or decriminalization frameworks. U.S. rescheduling could influence United Nations Commission on Narcotic Drugs deliberations on cannabis treaty scheduling, potentially leading to international reclassification that would facilitate cross-border research collaboration and medical access. Congressional legislation remains possible regardless of DEA action. The Cannabis Administration and Opportunity Act, introduced by Senate Majority Leader Chuck Schumer, would deschedule cannabis entirely and establish a federal regulatory framework. The bill has not advanced due to Republican opposition and concerns from some Democratic senators about youth access and impaired driving. Rescheduling could either reduce pressure for legislation by addressing industry concerns or increase momentum by demonstrating federal policy evolution.

Further Reading

• DEA Notice of Proposed Rulemaking on Cannabis Rescheduling (Federal Register, May 21, 2024): https://www.federalregister.gov/documents/2024/05/21/2024-10633/schedules-of-controlled-substances-rescheduling-of-marijuana
• HHS Recommendation to Reschedule Cannabis to Schedule III (August 30, 2023): https://www.hhs.gov/about/news/2023/08/30/hhs-recommends-rescheduling-marijuana.html
• Controlled Substances Act, 21 U.S.C. § 801 et seq.: https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13.htm
• DEA Administrative Hearing Procedures, 21 C.F.R. Part 1316: https://www.ecfr.gov/current/title-21/chapter-II/part-1316
• Internal Revenue Code Section 280E: https://www.law.cornell.edu/uscode/text/26/280E
• FDA Approval of Epidiolex (cannabidiol): https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms
• National Academies Report: The Health Effects of Cannabis and Cannabinoids (2017): https://nap.nationalacademies.org/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state
• Congressional Research Service: Marijuana: Medical and Retail—Selected Legal Issues (Updated 2024): https://crsreports.congress.gov
• State-by-state cannabis laws: https://www.mpp.org/states/
• NORML Legal Issues: https://norml.org/laws/

Update — June 18, 2026: Opposition Groups Frame June 29 Hearing as Test of 'Medical' Claims

Anti-legalization advocates intensified their messaging ahead of the June 29, 2026 DEA administrative hearing, arguing that the cannabis industry's reliance on medical terminology lacks the evidentiary foundation required under the Controlled Substances Act. According to statements circulated by opposition coalitions, the hearing will force proponents to defend rescheduling from Schedule I to Schedule III using FDA-standard clinical data rather than state-level patient testimonials or observational studies.

The framing reflects a strategic pivot by rescheduling opponents, who now focus on FDA approval standards and the absence of large-scale randomized controlled trials for whole-plant cannabis. Critics highlighted that Schedule III substances—including ketamine and anabolic steroids—carry approved medical uses documented through New Drug Applications, a regulatory pathway no cannabis product outside Epidiolex has completed. This argument directly challenges HHS's August 2023 recommendation, which cited accepted medical use based on state programs and physician prescribing patterns rather than federal drug approval.

Industry stakeholders preparing testimony for the hearing face pressure to address this evidentiary gap. Legal teams representing multi-state operators have reportedly shifted focus toward presenting peer-reviewed efficacy studies, international regulatory precedents from Germany and Israel, and economic data on patient access under state medical programs. The debate over what constitutes "accepted medical use" under 21 U.S.C. § 812 now sits at the center of the rescheduling case, with DEA Administrative Law Judge John Mulrooney expected to weigh competing interpretations of the statutory standard.

The rhetorical battle carries immediate compliance implications. If the DEA ultimately requires FDA-level proof for rescheduling, the timeline for any schedule change could extend years beyond the hearing's conclusion, forcing operators to maintain dual state-federal compliance postures and delaying access to 280E tax relief and interstate commerce pathways. Financial analysts noted that prolonged uncertainty may depress cannabis equity valuations and complicate capital raises scheduled for Q3 2026.